Quintrio
Home

SURGICAL & MEDICAL INSTRUMENTS & APPARATUS

NovoCure Limited Ordinary Shares

NVCR

NovoCure Ltd is an oncology company with a proprietary platform technology in the United States. Its business involves the development, manufacture, and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis, and other products and technologies for the treatment of Glioblastoma, Non-small cell lung cancer, and Pancreatic cancer. Geographically, the company derives the majority of its revenue from the United States and the rest from Germany, Japan, and other markets.

Last trade $11.14
Day change -$0.16 (-1.42%)
Day range $11.10 – $12.94
Volume 481,312
Market cap $1.32B

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$1.32B
Price / earnings
—
Price / book
3.77×
Price / sales
1.82×
EV / sales
1.96×
EV / EBITDA
-13.22×

Profitability

Earnings per share
-$1.04
Return on assets
-14.69%
Return on equity
-34.72%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0.56×
Current ratio
2.49×
Quick ratio
2.34×
Cash ratio
0.36×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$24.61M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for NVCR, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024
Revenue$193.4M$183.58M$174.06M$174.35M$167.2M$158.81M$154.99M$161.27M
Cost of revenue$44.53M$41.11M$38.93M$42.16M$44.73M$41.47M$38.52M$33.47M
Gross profit$148.87M$142.48M$135.13M$132.19M$122.48M$117.33M$116.47M$127.8M
Selling, general and administrative$96.94M$101.59M$144.21M$111.68M$104.47M$101.02M$100.56M$139.89M
Research and development$58.1M$51.45M$58.34M$60.91M$54.03M$55.83M$53.78M$51.21M
Total operating expenses$155.04M$153.04M$202.55M$172.59M$158.5M$156.85M$154.34M$191.1M
Operating income-$6.17M-$10.56M-$67.42M-$40.39M-$36.02M-$39.52M-$37.87M-$63.3M
Interest expense-$1.71M-$1.89M$0-$561K$6M$4.54M$0$0
Income before taxes-$7.88M-$12.45M-$69.26M-$40.95M-$30.02M-$34.98M-$30.3M-$55.21M
Income taxes$2.56M$3.21M$1.88M-$16.46M$7.25M$5.16M$4.02M$10.72M
Net income-$10.44M-$15.66M-$71.14M-$24.5M-$37.27M-$40.14M-$34.32M-$65.92M
Net income attributable to common shareholders-$10.44M-$15.66M-$71.14M-$24.5M-$37.27M-$40.14M-$34.32M-$65.92M
EBITDA-$1.76M-$6.26M-$63.3M-$36.18M-$32.36M-$36.08M-$34.54M-$60.2M
Basic earnings per share-$0.09-$0.13-$0.62-$0.22-$0.33-$0.36-$0.31-$0.61
Diluted earnings per share-$0.09-$0.13-$0.62-$0.22-$0.33-$0.36-$0.31-$0.61

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
The Motley Fool

FDA Rejects NovoCure’s Optune Mya for Lung Cancer Brain Metastases. Here's What It Means for Investors.

The FDA issued a not approvable letter for NovoCure's Optune Mya device for treating lung cancer brain metastases, citing uncertainty around clinical benefit despite no safety concerns. The rejection compounds investor concerns following lackluster Q3 earnings and competition from Revolution Medicines' newly approved Rasonque pill for pancreatic cancer. NovoCure's stock fell 7.34% on the news, and the analyst recommends against investing in the beaten-down equity.

The Motley Fool

NovoCure: 3 Key Takeaways for Long-Term Investors

NovoCure reported record Q3 2026 revenue of $193 million with 16% year-over-year growth, achieving adjusted EBITDA positivity. The company is expanding internationally with Japan emerging as its second-largest market, though pancreatic cancer product Optune Pax faces headwinds from competing drug diraxonrasib. Full-year guidance was raised to $736-743 million.

Zacks Investment Research

Novocure Reports Patient Data Exposure in Cybersecurity Incident

Novocure Limited (NVCR) disclosed unauthorized access to internal systems in mid-August 2026, exposing internal patient ID numbers for over 1,400 U.S. patients and contact information for healthcare providers and employees. The company stated that medical devices were not accessed, systems remained functional, and no material financial impact is expected. NVCR shares rose 3.2% since the September 1 disclosure.

The Motley Fool

Stock Market Today, June 4: Broadcom Drags on Nasdaq at Midday

Broadcom's disappointing AI-chip guidance triggered a semiconductor sell-off, dragging down the Nasdaq while the S&P 500 and Dow Jones gained on sector rotation and value tailwinds. Healthcare stocks rallied with Eli Lilly and NovoCure posting strong gains. The pullback raises questions about AI stock valuations and whether the semiconductor sector's 170% annual rally is cooling.

GlobeNewswire Inc.

Glioblastoma Multiforme Market Poised for Significant Growth at a CAGR of 13.2% During the Forecast Period (2026–2036), as Next-Generation Therapies Enter Late-Stage Development | DelveInsight

The glioblastoma multiforme market is expected to grow at a CAGR of 13.2% from 2026-2036, driven by next-generation therapies entering late-stage development. The market was valued at USD 900 million in 2025 across the 7MM, with approximately 38,000 incident cases. Key players including Avita Biomedical, Kazia Therapeutics, Laminar Pharma, and others are advancing innovative immunotherapies, targeted treatments, and personalized medicine approaches to address the poor prognosis of this aggressive brain tumor.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily

No stock split records found.